Price
No data yet.
Social Signal Score
Revenue
$75.25M+240709.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher R. Anzalone
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 711
- Beta
- 1.29
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.05
Financials
Revenue
$75.25M+240709.6%Net Income
$-194.28MEBITDA
$-154.34MFree Cash Flow
$-181.32MEPS (diluted)
$-1.36Shares Outstanding (diluted)
143.38M+100.7%Operating Expenses
$245.35MCash & Debt
$1.60BReturn of Capital
$38.43MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $829.45M | $-1.63M | $-0.01 |
| 2024 | $3.55M | $-599.49M | $-5.00 |
| 2023 | $240.74M | $-205.28M | $-1.92 |
| 2022 | $243.23M | $-176.06M | $-1.67 |
| 2021 | $138.29M | $-140.85M | $-1.36 |
| 2020 | $87.99M | $-84.55M | $-0.84 |
| 2019 | $168.80M | $67.97M | $0.72 |
| 2018 | $16.14M | $-54.45M | $-0.65 |
| 2017 | $31.41M | $-34.38M | $-0.47 |
| 2016 | $158.3K | $-81.72M | $-1.34 |
| 2015 | $382.0K | $-91.94M | $-1.60 |
| 2014 | $175.0K | $-58.63M | $-1.25 |
| 2013 | $290.3K | $-31.14M | $-1.30 |
| 2012 | $146.9K | $-21.13M | $-1.90 |
Valuation
ARWRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsbusinesswire.com·6h ago·Neutral
…armaceuticals to Present New Clinical Data at the European Society of Cardiology Congress PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany. ESC 2026 Presentation Details Date & Time: Sunday, August 30, 2026, 17:30 CEST Session Title: HOT LINE 9 Late-breaking Science Session Location: Munich Auditorium-Hall B3 Title: Plozasiran in patient…
View source ↗
Earnings
Tue, Nov 24(in 3 months)
Consensus estimate $-1.52 per share
Typical surprise -34.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.36 vs $-1.28miss
- Thu, May 7$-0.93 vs $-1.09beat
- Thu, Feb 5$0.22 vs $0.60miss
- Tue, Nov 25$-0.18 vs $-0.11miss
- Thu, Aug 7$-1.26 vs $-0.94miss
- Mon, May 12$2.75 vs $-0.06beat
Estimates and results for ARWR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARWR officers and directors.
- Bought
- —
- Sold
- $39.5m
0 trades
72 trades
- Olukotun Adeoye Ysold
- Perry Michael Ssold
- Lu Hongbosold
- Hamilton James Csold
- Apel Daniel Josephsold
- Apel Daniel Josephsold
- Apel Daniel Josephsold
- Hamilton James Csold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.